Navigation Links
Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
Date:10/21/2010

VIENNA, Oct. 21 /PRNewswire/ -- Intercell AG (VSE; "ICLL") and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug, nitazoxanide, during the first half of 2011.

Intercell's vaccine candidate has demonstrated a sustained reduction of viral load in chronic Hepatitis C (CHC) patients in a Phase II proof-of-concept trial. Nitazoxanide is an oral therapy that targets host cell factors involved in HCV replication and is not associated with viral mutations conferring resistance. Nitazoxanide has been shown to induce sustained virologic response as monotherapy in some patients chronically infected with HCV.

The planned European Phase II trial will include about 60 treatment-naïve patients chronically infected with HCV genotype-1 in three treatment arms: (1) IC41 plus nitazoxanide, (2) IC41 plus nitazoxanide and Pegasys® (peginterferon alfa-2a) and (3) Pegasys and Copegus® (ribavirin), the current standard of care, as an active control. The primary endpoint will be sustained virologic response (no detectable HCV RNA 24 weeks after end-of-treatment).

The companies involved in the combination study will retain commercial rights for their respective products.

"We are very pleased about this important next step in the development of our vaccine candidate against Hepatitis C. The distinctly different mode-of-action and the outstanding tolerability of both treatments create a joint approach in a field that will continue to have high unmet medical need over the next decades," stated Gerd Zettlmeissl, CEO of Intercell.

"We are excited about this novel therapeutic approach for chronic Hepatitis C," said Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark. "There is an important need for novel therapies that offer improvements in safety and efficacy com
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell AG Appoints Staph Leavenworth Bakali as Chief Business Officer
2. Intercell Acquires Antibody Technology Platform to Further Exploit Its Capabilities to Combat Infectious Diseases
3. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
4. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
5. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
6. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
7. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
8. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
9. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
10. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
11. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015  IntelliQuit™, the world,s first smartphone breathalyzer for smokers, was selected to present as ... New York City on Wednesday April 22.  ... ... ... Thirty percent (30%) of all cardiovascular disease is caused ...
(Date:4/21/2015)... ST. LOUIS , April 21, 2015 ... as a 5.4 percent decrease in utilization helped offset ... according to new data released today by Express Scripts ... Express Scripts Workers, Compensation Drug Trend Report discusses the ... opioid use among injured workers. Opioid ...
(Date:4/21/2015)... April 21, 2015  Navitas has launched Aviator, a ... range of offerings for life sciences clients. Aviator supports ... platform enabling seamless flow of data across all applications ... launch, Navitas worked closely with Oracle to provide Argus, ... CTMS in the Cloud. ...
Breaking Medicine Technology:IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 2IntelliQuit World's First Smartphone Breathalyzer for Smokers to Present to American Heart Association Innovation Investment Forum 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 2Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 3Workers' Compensation Prescription Drug Spend Increased 1.9 Percent in 2014, Stabilized by Effective Utilization Management Programs 4Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 2Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 3Navitas Launches Aviator - Cloud Based Platforms for Oracle Solutions 4
... June 21 Gentris Corporation ( www.gentris.com ), ... that Rick Williams has joined the organization ... Board of Directors.  In his role as CEO of ... continues to provide biotechnology and pharmaceutical sponsors with the ...
... 21 Thomson Reuters announced today that it has launched ... the way biotechnology, pharmaceutical and academic organizations find partnering opportunities around ... , ... with drugs in development. It enables authorized users to share essential ...
Cached Medicine Technology:Gentris Corporation Names New Chief Executive Officer 2Gentris Corporation Names New Chief Executive Officer 3Gentris Corporation Names New Chief Executive Officer 4Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 2Thomson Reuters Creates The Outpartnering Registry, a Free Resource to Improve Drug Development Partnering 3
(Date:4/21/2015)... Chicago, IL (PRWEB) April 21, 2015 ... surgery provider in India for their ongoing commitment to ... Hyderabad strives to provide patients with the best ... to the skin, hair and body. , Executives at ... believes in the philosophy of — nothing about you, ...
(Date:4/21/2015)... Lewisville, TX (PRWEB) April 21, 2015 ... (NYSE:ADPT) announced today it is opening its first freestanding ... located in Chandler, Arizona and will be licensed under ... of the Dignity Health and Adeptus Health joint venture. ... Chandler Regional and Mercy Gilbert Medical Centers said the ...
(Date:4/21/2015)... Information is the best weapon in the fight ... patients and their families with knowledge about living with cancer ... is the Answer" and new website . , In ... patients from diagnosis through treatment and even death. The goal, ... treatment, at home and in the examination room. , “Cancer ...
(Date:4/21/2015)... Lowcostcarinsuranceprice.com has released a new blog post explaining ... SUVs. , SUVs are large vehicles that fare well ... and a smaller regular car shows that passengers from the ... SUV safer in crashes, but these large vehicles may be ... , It is now possible to find low cost car ...
(Date:4/21/2015)... QuickMedical, a veteran-owned leader in the ... Schiller America's line of Ambulatory and ... Vital Signs Monitors, among many other items. ... leader in the development and production of cardio-pulmonary ... cooperation with the world's leading physicians and specialists ...
Breaking Medicine News(10 mins):Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 2Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 3Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 3Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2Health News:Auto Insurance Quotes For SUVs Are Available Online 2Health News:QuickMedical Launches New Product Line: Schiller America 2Health News:QuickMedical Launches New Product Line: Schiller America 3
... world-leading publisher of scientific, technical, and medical information products ... January 2009, the internationally respected Journal of Pain ... be the official journal of the American Academy of ... will continue to serve as the official journal ...
... in Laser and Endoscopic Surgery , , ... Schaeffer, endoscopic reconstructive surgeon and leading nasal expert, has retained ... cosmetic practice. , , ... face, neck, sinuses and skull base, Dr. Schaeffer is credited ...
... 17 Cadence Pharmaceuticals, Inc.,(Nasdaq: CADX ... 304, a,Phase III clinical trial of Acetavance(TM), the ... acute pain following,abdominal laparoscopic surgery. Study 304 ... reduction in summed pain intensity,differences from baseline over ...
... NEW YORK, Dec. 17 Forest Laboratories, Inc. (NYSE: ... Chief Executive Officer exercised stock options for 600,000 shares which ... their 10-year term. Mr. Solomon indicated his intent to ... option exercise, net of those shares withheld by the Company ...
... is linked to hepatitis B, researchers say , , ... increased overall survival in Asian-Pacific patients with advanced liver ... included 226 patients in China, South Korea and Taiwan. ... 400 milligrams of sorafenib (Nexavar) twice a day in ...
... Internet,s fastest-growing job site, predicts the job sectors most likely to ... ... McLean, VA (PRWEB) December 17, 2008 -- Jobfox, the ... trends to watch in 2009. The list includes the job ...
Cached Medicine News:Health News:Elsevier announces new partnership between the Journal of Pain and Symptom Management and the AAHPM 2Health News:Rubenstein Public Relations Retained To Provide Publicity for Foremost Nasal and Cosmetic Surgeon 2Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 2Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 3Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 4Health News:Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery 5Health News:Forest Laboratories Announces Executive Exercised Stock Options With Intent to Hold Shares 2Health News:Drug Helps Asians Battling Liver Cancer 2Health News:The Obama Effect: New Job Trends to Watch in 2009 2Health News:The Obama Effect: New Job Trends to Watch in 2009 3
... The Fundus 20mm is a ... Lens. The Fundus 20mm provides ... increased 20mm contact element. The ... the contact element sits under ...
... The Volk Area Centralis® is excellent ... neovascularization and changes from macular degeneration, ... proliferative diabetic retinopathy and other retinal ... laser treatment of these conditions providing ...
... delivers the widest field of view ... .5x image magnification provides simultaneous visualization of ... providing a greater margin of safety during ... the ideal lens for visualization and treatment ...
... it the "Super 90". Volk's SuperField® has ... diagnosis for today's discriminating practitioner. Its ideal ... make it perfect as the primary high ... SuperField has been specifically designed for increased ...
Medicine Products: